These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 21319020)

  • 1. Three cases of bortezomib-resistant multiple myeloma with extramedullary masses.
    Moriuchi M; Ohmachi K; Kojima M; Tsuboi K; Ogawa Y; Nakamura N; Ando K
    Tokai J Exp Clin Med; 2010 Apr; 35(1):17-20. PubMed ID: 21319020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment with a proteasome inhibitor, bortezomib, for thalidomide-resistant multiple myeloma].
    Takatoku M; Noborio-Hatano K; Takahashi S; Kikuchi S; Mori M; Muroi K; Komatsu N; Ozawa K
    Rinsho Ketsueki; 2004 Feb; 45(2):144-8. PubMed ID: 15045823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
    Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
    Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New drugs for myeloma.
    Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K
    Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors.
    Dimopoulos MA; Roussou M; Gavriatopoulou M; Zagouri F; Migkou M; Matsouka C; Barbarousi D; Christoulas D; Primenou E; Grapsa I; Terpos E; Kastritis E
    Clin Lymphoma Myeloma; 2009 Aug; 9(4):302-6. PubMed ID: 19717380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenalidomide is effective for the treatment of bortezomib-resistant extramedullary disease in patients with multiple myeloma: report of 2 cases.
    Ito C; Aisa Y; Mihara A; Nakazato T
    Clin Lymphoma Myeloma Leuk; 2013 Feb; 13(1):83-5. PubMed ID: 23103083
    [No Abstract]   [Full Text] [Related]  

  • 7. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
    Laubach JP; Schlossman RL; Mitsiades CS; Anderson KC; Richardson PG
    Expert Rev Hematol; 2011 Feb; 4(1):51-60. PubMed ID: 21322778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.
    Bladé J; Cibeira MT; Rosiñol L
    Acta Oncol; 2005; 44(5):440-8. PubMed ID: 16118077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma.
    Richardson PG; Mitsiades C; Ghobrial I; Anderson K
    Curr Opin Oncol; 2006 Nov; 18(6):598-608. PubMed ID: 16988581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series.
    Wolf J; Richardson PG; Schuster M; LeBlanc A; Walters IB; Battleman DS
    Clin Adv Hematol Oncol; 2008 Oct; 6(10):755-60. PubMed ID: 18997666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma.
    Zangari M; Esseltine D; Lee CK; Barlogie B; Elice F; Burns MJ; Kang SH; Yaccoby S; Najarian K; Richardson P; Sonneveld P; Tricot G
    Br J Haematol; 2005 Oct; 131(1):71-3. PubMed ID: 16173965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.
    Jagannath S; Barlogie B; Berenson JR; Singhal S; Alexanian R; Srkalovic G; Orlowski RZ; Richardson PG; Anderson J; Nix D; Esseltine DL; Anderson KC;
    Cancer; 2005 Mar; 103(6):1195-200. PubMed ID: 15690325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current status of new drugs for the treatment of patients with multiple myeloma.
    Kenealy M; Prince HM
    Intern Med J; 2006 Dec; 36(12):781-9. PubMed ID: 17096741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effectiveness of bortezomib and bortezomib-containing programs for the treatment of recurrent and resistant multiple myeloma].
    Mitina TA; Golenkov AK; Kataeva EV; Lutskaia TD; Trifonova EV; Klinushkina EF
    Ter Arkh; 2010; 82(7):57-61. PubMed ID: 20853611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloablative allogeneic transplantation.
    Patriarca F; Prosdocimo S; Tomadini V; Vasciaveo A; Bruno B; Fanin R
    Haematologica; 2005 Feb; 90(2):278-9. PubMed ID: 15710593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.
    Berenson JR; Jagannath S; Barlogie B; Siegel DT; Alexanian R; Richardson PG; Irwin D; Alsina M; Rajkumar SV; Srkalovic G; Singhal S; Limentani S; Niesvizky R; Esseltine DL; Trehu E; Schenkein DP; Anderson K
    Cancer; 2005 Nov; 104(10):2141-8. PubMed ID: 16206291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib and extramedullary disease in multiple myeloma: the shine and dark side of the moon.
    Ali R; Ozkalemkas F; Ozkan A; Ozkocaman V; Ozcelik T; Ozan U; Kurt M; Tunali A
    Leuk Res; 2007 Aug; 31(8):1153-5. PubMed ID: 16945413
    [No Abstract]   [Full Text] [Related]  

  • 18. Unusual discordant responses in two multiple myeloma patients during bortezomib treatment.
    Pirrotta MT; Gozzetti A; Cerase A; Bucalossi A; Bocchia M; Defina M; Lauria F
    Onkologie; 2008 Feb; 31(1-2):45-7. PubMed ID: 18268398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib therapy following first relapse.
    Orlowski RZ;
    Oncology (Williston Park); 2005 Jan; 19(1):23-6. PubMed ID: 15743149
    [No Abstract]   [Full Text] [Related]  

  • 20. Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib.
    Anargyrou K; Terpos E; Vassilakopoulos TP; Pouli A; Sachanas S; Tzenou T; Masouridis S; Christoulas D; Angelopoulou MK; Dimitriadou EM; Kalpadakis C; Tsionos K; Panayiotidis P; Dimopoulos MA; Pangalis GA; Kyrtsonis MC;
    Haematologica; 2008 Mar; 93(3):451-4. PubMed ID: 18287135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.